XTSX
VXL
Market cap400kUSD
Jul 15, Last price
0.20CAD
1D
0.00%
Jan 2017
100.00%
IPO
-91.07%
Name
Vaxil Bio Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.98%
Rev. gr., 5y
%
Revenues
0k
Net income
0k
L-99.96%
CFO
-561k
L-23.57%
Profile
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 254 | 584 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (254) | (584) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (254) | (584) | |||||||
Net income | (254) -99.96% | (584) -40.77% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (938) | (1,510) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (561) | (734) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | (254) | (582) | |||||||
| Balance | |||||||||
Cash | 938 | 1,510 | |||||||
Long term investments | |||||||||
Excess cash | 938 | 1,510 | |||||||
Stockholders' equity | 891 | 812 | |||||||
Invested Capital | 324 | ||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 136,978 | 136,979 | |||||||
Price | 0.03 25.00% | 0.02 -73.33% | |||||||
Market cap | 3,424 25.00% | 2,740 -73.16% | |||||||
EV | 2,486 | 1,230 | |||||||
EBITDA | (254) | (582) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||